542934
CBPL
Start SIP
Invest Now
Start SIP in CBPL
Performance
- Low
- ₹42
- High
- ₹42
- 52 Week Low
- ₹33
- 52 Week High
- ₹73
- Open Price₹42
- Previous Close₹42
- Volume2,000
- 50 DMA₹46.63
- 100 DMA₹53.76
- 200 DMA₹66.03
Investment Returns
- Over 1 Month + 7.68%
- Over 3 Month + 5.47%
- Over 6 Month -23.27%
- Over 1 Year -33.02%
Smart Investing Starts Here Start SIP with Chandra Bhagat Pharma for Steady Growth!
Chandra Bhagat Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 37.1
- PEG Ratio
- -
- Market Cap Cr
- 32
- P/B Ratio
- 1
- Average True Range
- 2.43
- EPS
- -
- Dividend Yield
- 0
- MACD Signal
- -1.95
- RSI
- 47.65
- MFI
- 59.03
Chandra Bhagat Pharma Financials
Chandra Bhagat Pharma Technicals
EMA & SMA
Current Price
₹42.20
+
0.1
(0.24%)
- Bearish Moving Average 10
- Bullish Moving Average 6
- 20 Day
- ₹42.24
- 50 Day
- ₹46.63
- 100 Day
- ₹53.76
- 200 Day
- ₹66.03
Resistance and Support
42.2
- R3 42.20
- R2 42.20
- R1 42.20
- S1 42.20
- S2 42.20
- S3 42.20
Chandra Bhagat Pharma Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2025-11-13 | Half Yearly Results | |
| 2025-05-29 | Audited Results | |
| 2024-11-13 | Half Yearly Results | |
| 2024-05-30 | Audited Results | |
| 2023-11-09 | Half Yearly Results |
Chandra Bhagat Pharma F&O
About Chandra Bhagat Pharma
- NSE Symbol
- CBPL
- BSE Symbol
- 542934
- Chairman & Managing Director
- Mr. Hemant Chandravadan Bhagat
- ISIN
- INE07QQ01016
Similar Stocks to Chandra Bhagat Pharma
Chandra Bhagat Pharma FAQs
Chandra Bhagat Pharma share price is ₹42 As on 12 February, 2026 | 02:28
The Market Cap of Chandra Bhagat Pharma is ₹31.8 Cr As on 12 February, 2026 | 02:28
The P/E ratio of Chandra Bhagat Pharma is 37.1 As on 12 February, 2026 | 02:28
The PB ratio of Chandra Bhagat Pharma is 1 As on 12 February, 2026 | 02:28
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.